Dyne Therapeutics — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications0liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
DYNE-251The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension (LTE) period (288 weeks).	Myopathies	Phase 1/2	À vérifier	United States, Australia, Belgium, Canada, Ireland, Italy, South Korea, Spain, …	À vérifier
zeleciment basivarsen (DYNE-101)The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).	Myopathies	Phase 3	À vérifier	United States, Australia, Belgium, Denmark, France, Germany, Italy, Japan, …	À vérifier
Zeleciment Rostudirsen (DYNE-251)The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.	Myopathies	Phase 3	À vérifier	United States	À vérifier
DYNE-251The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension (LTE) period (288 weeks).	Myopathies	Phase 1/2	À vérifier	United States, Australia, Belgium, Canada, Ireland, Italy, South Korea, Spain, United Kingdom	À vérifier
zeleciment basivarsen (DYNE-101)The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).	Myopathies	Phase 3	À vérifier	United States, Australia, Belgium, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom	À vérifier
Zeleciment Rostudirsen (DYNE-251)The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.	Myopathies	Phase 3	À vérifier	United States	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
Zeleciment Rostudirsen (DYNE-251)	Myopathies	Phase 3	NCT07608432	Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)	RECRUITING
zeleciment basivarsen (DYNE-101)	Myopathies	Phase 3	NCT07486934	Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1	RECRUITING
DYNE-251	Myopathies	Phase 1/2	NCT05524883	DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.